Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 07-22 21:04:33时区推断·⟳ 抓取 07-22 21:07:14·⚡ 决策 07-23 08:24:40 +11h17m·96.4 天前
Co-Diagnostics印度合资公司启动结核病检测临床研究
CoSara已在印度启动基于CoSara PCR Pro的结核病检测临床研究，并已收到PCR Pro仪器、结核检测试剂盒和样本处理设备。
📄 原文Investing.com↗ 原文
Co-Diagnostics joint venture begins TB test clinical studies in India
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven? SALT LAKE CITY - Co-Diagnostics Inc. (NAS…
不做 Co-Diagnostics（CODX.US）
临床研究启动离监管批准和销售仍远，且无商业金额、定价或收入分成量级，当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 medium · price-in 风险 medium ↗
关键理由
- CoSara已在印度启动基于CoSara PCR Pro的结核病检测临床研究，并已收到PCR Pro仪器、结核检测试剂盒和样本处理设备。
- 平台仍需相关监管机构审查或授权，且Co-Dx PCR平台尚未在相关司法辖区获准销售。
主要风险
- 临床研究启动不是获批或商业销售，未披露样本规模、审批时间、定价和收入分成，当前难以量化新增收入。
原文全文
展开原文 · 1,792 字
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
SALT LAKE CITY - Co-Diagnostics Inc. (NASDAQ:CODX) announced today that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has initiated clinical studies for a tuberculosis test on the CoSara PCR Pro instrument, according to a press release statement.
The studies follow the shipment of PCR Pro instruments, mycobacterium tuberculosis test kits and sample preparation instruments to CoSara. The CoSara PCR Pro instrument, a branded version of the Co-Dx PCR Pro point-of-care instrument, is being deployed in select laboratories across India for TB testing evaluation.
The platform uses patented Co-Primers technology to deliver real-time PCR results in approximately 30 minutes via a mobile application. PCR test kits and the sample lysis instrument are expected to be manufactured and distributed in India under the CoSara brand.
CoSara Diagnostics is a joint venture between Co-Diagnostics and Synbiotics Ltd., a subsidiary of Ambalal Sarabhai Enterprises Ltd. The venture was established in 2017 to manufacture and commercialize molecular diagnostic instruments and assays in India.
The Co-Dx PCR platform, including the PCR Home, PCR Pro, mobile app and associated tests, is subject to review or authorization by applicable regulatory authorities in the jurisdictions where clearance or approval is sought, including the U.S. Food and Drug Administration, and is not yet available for sale.
Co-Diagnostics is a Utah-based molecular diagnostics company that develops, manufactures and markets diagnostic technologies for tests designed using the detection and analysis of nucleic acid molecules.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SALT LAKE CITY - Co-Diagnostics Inc. (NASDAQ:CODX) announced today that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has initiated clinical studies for a tuberculosis test on the CoSara PCR Pro instrument, according to a press release statement.
The studies follow the shipment of PCR Pro instruments, mycobacterium tuberculosis test kits and sample preparation instruments to CoSara. The CoSara PCR Pro instrument, a branded version of the Co-Dx PCR Pro point-of-care instrument, is being deployed in select laboratories across India for TB testing evaluation.
The platform uses patented Co-Primers technology to deliver real-time PCR results in approximately 30 minutes via a mobile application. PCR test kits and the sample lysis instrument are expected to be manufactured and distributed in India under the CoSara brand.
CoSara Diagnostics is a joint venture between Co-Diagnostics and Synbiotics Ltd., a subsidiary of Ambalal Sarabhai Enterprises Ltd. The venture was established in 2017 to manufacture and commercialize molecular diagnostic instruments and assays in India.
The Co-Dx PCR platform, including the PCR Home, PCR Pro, mobile app and associated tests, is subject to review or authorization by applicable regulatory authorities in the jurisdictions where clearance or approval is sought, including the U.S. Food and Drug Administration, and is not yet available for sale.
Co-Diagnostics is a Utah-based molecular diagnostics company that develops, manufactures and markets diagnostic technologies for tests designed using the detection and analysis of nucleic acid molecules.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。